US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

209.63

-18.1250-7.96%

Volume:423.21K

Turnover:90.48M

Market Cap:529.20M

PE:- -

High:223.71

Open:220.01

Low:208.30

Close:227.75

52wk High:341.93

52wk Low:102.35

Shares:2.52M

Float Shares:2.52M

Volume Ratio:1.86

T/O Rate:16.76%

Dividend:0.91

Dividend Rate:0.43%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)

Otsuka Subsidiary Initiates US FDA Submission for Kidney Disease Drug

MT Newswires Live

Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial

MT Newswires Live

Health Care Roundup: Market Talk

Wave Life Sciences: FDA-Aligned AATD Registrational Path, Obesity Combination Study, and GSK Milestones Underscore Buy Rating and $42 Price Target

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Labcorp Holdings (LH) and Surgery Partners (SGRY)

AstraZeneca (AZN) Receives a Buy from Berenberg Bank

Barclays Remains a Hold on HCA Healthcare (HCA)

Aveanna Healthcare Holdings (AVAH) Gets a Buy from Barclays

PTC Therapeutics (PTCT) Gets a Buy from Barclays

Sotera Health (SHC) Gets a Buy from RBC Capital

NIB Holdings Seeks ASX Quotation for New Dividend Plan Shares

Macquarie Remains a Buy on HealthCo Healthcare & Wellness REIT (HCW)

Analyst Maintains Buy on Enliven, Citing FDA-Aligned Phase III ENABLE-2 Trial and Valuation Disconnect as Attractive Entry Point

Health Care Down on Rotation to Utilities

HeartSciences Secures FDA Clearance for MyoVista wavECG

Bausch + Lomb to Advance Eye Disease Treatment Following FDA Meeting

Health Care Roundup: Market Talk

Press Release: Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation

Is Debt Refinancing Altering The Investment Case For Tenet Healthcare Stock?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LABU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":209.625,"timestamp":1791476231310,"preClose":227.75,"halted":0,"volume":423209,"delay":0,"changeRate":-0.07958287596048298,"floatShares":2524486,"shares":2524486,"eps":0,"marketStatus":"Trading","change":-18.125,"latestTime":"10-08 12:17:12 EDT","open":220.01,"high":223.7074,"low":208.3,"amount":90481330.88798,"amplitude":0.06765,"askPrice":210.55,"askSize":175,"bidPrice":209.61,"bidSize":100,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":227.75,"sharesOutstanding":3074486,"nav":230.529,"aum":581967299.18,"dividendRate":0.004346,"bidAskSpread":0.002401,"preHourTrading":{"tag":"盘前","latestPrice":220.18,"preClose":227.75,"latestTime":"09:29 EDT","volume":6169,"amount":1385605.45651,"timestamp":1791466199999,"change":-7.57,"changeRate":-0.033238,"amplitude":0.038727},"postHourTrading":{"tag":"盘后","latestPrice":228.7,"preClose":227.75,"latestTime":"19:59 EDT","volume":2729,"amount":623483.6155,"timestamp":1791417573520,"change":0.95,"changeRate":0.004171,"amplitude":0.004911},"volumeRatio":1.86267,"impliedVol":0.9725,"impliedVolPercentile":0.7251},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2524486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.86267,"shares":2524486,"dividePrice":0.911,"high":223.7074,"amplitude":0.06765,"preClose":227.75,"low":208.3,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":209.625,"committee":-0.272727,"eps":0,"divideRate":0.004346,"volume":423209,"delay":0,"ttmEps":0,"open":220.01,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":249.65,"twentyDayClose":266,"sixtyDayClose":277.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673509465","title":"Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673509465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673509465?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:50","pubTimestamp":1791366612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ArriVent BioPharma, Inc. (AVBP), Definium Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arrivent-biopharma-inc-avbp-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-arrivent-biopharma-inc-avbp-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","AVBP","BK4588","BK4007","BK4139","XLV","LU0029874061.USD","BK4585","HCSG","XBI","BK4137","LABU","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673423099","title":"Otsuka Subsidiary Initiates US FDA Submission for Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2673423099","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673423099?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:03","pubTimestamp":1791363820,"startTime":"0","endTime":"0","summary":"Otsuka  said its wholly owned unit, Otsuka Pharmaceutical Development & Commercialization, completed a rolling submission application to the US Food and Drug Administration for approval of its sibeprenlimab, Voyxact, on Tuesday.The Japan-based drug maker said that the drug is used to reduce proteinuria in adults with IgA nephropathy at risk for disease progression, according to a Wednesday filing with the Tokyo bourse.The company said that the drug secured accelerated approval last year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709943","title":"Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709943","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709943?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:01","pubTimestamp":1791363707,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  is on track to start its phase 3 trial of relcobatinib in patients with previously treated chronic myeloid leukemia before the end of 2026, the company said Wednesday.The move comes after the company aligned with the US Food and Drug Administration on the trial's final design.The trial is designed to directly compare relcobatinib with second-generation tyrosine kinase inhibitors and is expected to enroll 450 adults with chronic myeloid leukemia.The primary endpoint is major molecular response at week 24, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","BK4139","BK4588","ELVN","LABU","BK4585","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673274096","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2673274096","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673274096?lang=en_us&edition=fundamental","pubTime":"2026-10-07 16:20","pubTimestamp":1791361200,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0318 GMT - Top Glove's earnings have likely peaked and could tre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6511","BK6103","RGLO","JOYT","VOTE","XLV","BK4581","FEBU","BVA.SI","PMDE","BK4585","GXDW","VGFPF","BK4588","DECU","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673096445","title":"Wave Life Sciences: FDA-Aligned AATD Registrational Path, Obesity Combination Study, and GSK Milestones Underscore Buy Rating and $42 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673096445","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673096445?lang=en_us&edition=fundamental","pubTime":"2026-10-07 16:15","pubTimestamp":1791360927,"startTime":"0","endTime":"0","summary":"Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Wave Life Sciences, with a price target of $42.00. Whitney Ijem has given his ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/wave-life-sciences-fda-aligned-aatd-registrational-path-obesity-combination-study-and-gsk-milestones-underscore-buy-rating-and-42-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/wave-life-sciences-fda-aligned-aatd-registrational-path-obesity-combination-study-and-gsk-milestones-underscore-buy-rating-and-42-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673096441","title":"Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Labcorp Holdings (LH) and Surgery Partners (SGRY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673096441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673096441?lang=en_us&edition=fundamental","pubTime":"2026-10-07 16:10","pubTimestamp":1791360615,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX), Labcorp Holdings (LH) and Surg...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biontech-se-bntx-labcorp-holdings-lh-and-surgery-partners-sgry-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biontech-se-bntx-labcorp-holdings-lh-and-surgery-partners-sgry-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0516423091.SGD","LABU","LU0048573561.USD","BK4548","LU2177674079.SGD","SG9999013486.USD","LU0516422952.EUR","SG9999014492.USD","HCSG","LU0572939691.SGD","LU0006061336.USD","SG9999013460.SGD","BK4503","LU0251131958.USD","LU1048588211.SGD","SG9999001135.SGD","SE","SG9999006266.SGD","LU2008162690.USD","LU2065170008.USD","BK4139","LU0210637038.USD","LU0737861269.HKD","LU0345776255.USD","BK4551","LU0251143029.SGD","IE0031814969.USD","LU1059921491.USD","BK4196","FDNI","LU0264606111.USD","BNTX","LU2065171402.SGD","SG9999002406.SGD","XBI","LU1242518857.USD","XLV","LU0345775950.USD","LH","LU0499858438.USD","LU0251142724.SGD","LU2045819591.USD","BK4220","BK4550","LU2360107671.USD","SGRY","BK4566","SG9999002414.USD","BK4185","LU0348788117.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673809626","title":"AstraZeneca (AZN) Receives a Buy from Berenberg Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2673809626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673809626?lang=en_us&edition=fundamental","pubTime":"2026-10-07 16:07","pubTimestamp":1791360458,"startTime":"0","endTime":"0","summary":"Berenberg Bank analyst Luisa Hector maintained a Buy rating on AstraZeneca today and set a price target of £150.00. Hector covers the Healthcare se...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-berenberg-bank-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-berenberg-bank-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZN","LABU","LU0889565916.HKD","LU2456880835.USD","BK4568","LU0289739699.SGD","LU2236285917.USD","LU0432979614.USD","LU0310800379.SGD","LU2462157665.USD","LU2237443549.SGD","LU0058720904.USD","LU0708994859.HKD","BK4007","LU2237443895.HKD","IE00B3T34201.USD","LU0109394709.USD","LU0029864427.USD","LU1829250122.USD","LU2237443382.USD","XBI","BK4581","LU2237443978.SGD","LU0320765992.SGD","BK4588","LU2089984988.USD","LU2237443622.USD","AZNH","LU2237443465.HKD","LU0128525929.USD","LU2468319806.SGD","LU2417539215.USD","BK4585","XLV","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673962880","title":"Barclays Remains a Hold on HCA Healthcare (HCA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673962880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673962880?lang=en_us&edition=fundamental","pubTime":"2026-10-07 16:07","pubTimestamp":1791360447,"startTime":"0","endTime":"0","summary":"In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on HCA Healthcare, with a price target of $387.00. Mok CFA covers...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-hca-healthcare-hca-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-hca-healthcare-hca-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999014039.USD","LU1201861249.SGD","SG9999014021.USD","LU0211328371.USD","HCA","LU0203347892.USD","LU0114720955.EUR","LU1261432733.SGD","LU0882574055.USD","LU0068578508.USD","IE00B775SV38.USD","LU1084165304.USD","LU0985489474.SGD","IE00B3S45H60.SGD","LU0203345920.USD","LU1489326972.SGD","LU0648001328.SGD","LU2355687059.USD","BK4588","LU0211327993.USD","SG9999014013.SGD","LU0433182093.SGD","LU1150488218.USD","LU0980610538.SGD","LU1267930573.SGD","XLV","LU1267930490.SGD","BK4185","BK4581","LU0029864427.USD","IHF","BK4585","LU0130102774.USD","LU1150488135.SGD","LU0310799852.SGD","LU1119994496.HKD","LU0878866978.SGD","LU0708994859.HKD","CFA","SG9999014005.SGD","LABU","LU2244417387.USD","LU0868494617.USD","BK4504","LU0128525929.USD","LU0187121727.USD","XBI","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673472096","title":"Aveanna Healthcare Holdings (AVAH) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673472096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673472096?lang=en_us&edition=fundamental","pubTime":"2026-10-07 16:06","pubTimestamp":1791360386,"startTime":"0","endTime":"0","summary":"In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Aveanna Healthcare Holdings, with a price target of $15.00. Acc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aveanna-healthcare-holdings-avah-gets-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aveanna-healthcare-holdings-avah-gets-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CFA","BK4588","BK4581","BK4585","XLV","BK4196","XBI","AVAH","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673538096","title":"PTC Therapeutics (PTCT) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673538096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673538096?lang=en_us&edition=fundamental","pubTime":"2026-10-07 15:57","pubTimestamp":1791359860,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle maintained a Buy rating on PTC Therapeutics today and set a price target of $122.00. Merle covers the Healthcare sect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ptc-therapeutics-ptct-gets-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ptc-therapeutics-ptct-gets-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4585","BK4139","LU0889565916.HKD","LABU","PTCT","XBI","LU0320765992.SGD","BK4588","BK4581","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673064189","title":"Sotera Health (SHC) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673064189","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673064189?lang=en_us&edition=fundamental","pubTime":"2026-10-07 09:49","pubTimestamp":1791337789,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Ryan Halsted maintained a Buy rating on Sotera Health yesterday and set a price target of $24.00. Halsted covers the Healthcare...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sotera-health-shc-gets-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sotera-health-shc-gets-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GSIB","LU0708994859.HKD","BK4585","SHC","BK4207","LU0310800379.SGD","LU0029864427.USD","LU0128525929.USD","LU1267930573.SGD","BK4581","XLV","BK4121","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673061934","title":"NIB Holdings Seeks ASX Quotation for New Dividend Plan Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673061934","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673061934?lang=en_us&edition=fundamental","pubTime":"2026-10-07 08:27","pubTimestamp":1791332878,"startTime":"0","endTime":"0","summary":"NIB Holdings Ltd ( ($AU:NHF) ) has issued an update. NIB Holdings Limited is an Australian listed health insurance provider focused on offering pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nib-holdings-seeks-asx-quotation-for-new-dividend-plan-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nib-holdings-seeks-asx-quotation-for-new-dividend-plan-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","UNHW","UNHG","IHF","UNHU","XBI","XLV","UN","BK4581","LABU","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673660930","title":"Macquarie Remains a Buy on HealthCo Healthcare & Wellness REIT (HCW)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673660930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673660930?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:36","pubTimestamp":1791326179,"startTime":"0","endTime":"0","summary":"Macquarie analyst maintained a Buy rating on HealthCo Healthcare & Wellness REIT today and set a price target of A$1.10. Currently, the analyst con...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/macquarie-remains-a-buy-on-healthco-healthcare-wellness-reit-hcw-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/macquarie-remains-a-buy-on-healthco-healthcare-wellness-reit-hcw-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REIT","IVRA","PSCF","MDIV","XLV","YLDW","BK4585","BK4588","XBI","BK4581","BPRE","LABU","RNTY","DFRA","RJMG","IQRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066216","title":"Analyst Maintains Buy on Enliven, Citing FDA-Aligned Phase III ENABLE-2 Trial and Valuation Disconnect as Attractive Entry Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066216","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066216?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:15","pubTimestamp":1791324929,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has reiterated their bullish stance on ELVN stock, giving a Buy rating yesterday. Andy Hsieh has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-enliven-citing-fda-aligned-phase-iii-enable-2-trial-and-valuation-disconnect-as-attractive-entry-point-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-enliven-citing-fda-aligned-phase-iii-enable-2-trial-and-valuation-disconnect-as-attractive-entry-point-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066503","title":"Health Care Down on Rotation to Utilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066503","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066503?lang=en_us&edition=fundamental","pubTime":"2026-10-07 05:44","pubTimestamp":1791323040,"startTime":"0","endTime":"0","summary":"Health-care companies ticked down as a rotation to other defensive sectors offset deal activity.Investment firm CD&R and drug wholesaler McKesson agreed to buy Option Care Health, a provider of infusi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","XBI","BK4581","BK4588","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673065096","title":"HeartSciences Secures FDA Clearance for MyoVista wavECG","url":"https://stock-news.laohu8.com/highlight/detail?id=2673065096","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673065096?lang=en_us&edition=fundamental","pubTime":"2026-10-07 05:02","pubTimestamp":1791320554,"startTime":"0","endTime":"0","summary":"Heart Test Laboratories, Inc. ( ($HSCS) ) has provided an announcement. On October 6, 2026, HeartSciences announced that the U.S. Food and Drug Adm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/heartsciences-secures-fda-clearance-for-myovista-wavecg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/heartsciences-secures-fda-clearance-for-myovista-wavecg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673406595","title":"Bausch + Lomb to Advance Eye Disease Treatment Following FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673406595","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673406595?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:51","pubTimestamp":1791319860,"startTime":"0","endTime":"0","summary":"Bausch + Lomb said it plans to advance one of its eye disease treatments following a meeting with the Food and Drug Administration it described as constructive.The eye health company said the FDA meeting gave clarity on the development path of BL1243, or tonabersat, a treatment of dry age-related macular degeneration.The FDA was supportive in principle of a proposed initial study design, the company said, adding that results from the initial study are expected to support advancement into a phase 2 study. The clinical program in dry AMD is expected to launch in 2027.\"The oral route of administration, prior clinical experience and potential application in earlier-stage disease make BL1243 a particularly compelling program as we continue building the next generation of treatments for eye health,\" Chief Medical Officer Yehia Hashad said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673065930","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2673065930","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673065930?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:50","pubTimestamp":1791319800,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0310 ET - Sanofi needs mergers and acquisitions to refill its la","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4588","XLV","XBI","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673479063","title":"Press Release: Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673479063","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673479063?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:15","pubTimestamp":1791317700,"startTime":"0","endTime":"0","summary":"Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segmentsProceeds strengthen balance sheet and enhance financial flexibilityLONDON, Oct. 6, 2026 /PRNewsw","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0128526141.USD","BK4588","XLV","XBI","CLVT","BK4585","HCSG","BK4561","LU0029874061.USD","LABU","BK4137","BK4123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673680220","title":"Is Debt Refinancing Altering The Investment Case For Tenet Healthcare Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673680220","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673680220?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:18","pubTimestamp":1791314282,"startTime":"0","endTime":"0","summary":"Tenet Healthcare has issued US$2b of 6.250% senior notes due 2034, with the proceeds intended to redeem US$1.5b of 5.125% secured notes due 2027 and US$500m of 6.125% notes due 2028, reshaping its long term debt stack.\nThis refinancing moves Tenet Healthcare toward longer dated unsecured borrowing while leaving room for additional indebtedness, which affects future flexibility for hospital investments, ambulatory surgery center expansion and ongoing share repurchases.\nWe will look at how...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6033000-choice1-card/1788938511465","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6033000-choice1-card/1788938511465"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-thc/tenet-healthcare/news/is-debt-refinancing-altering-the-investment-case-for-tenet-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-thc/tenet-healthcare/news/is-debt-refinancing-altering-the-investment-case-for-tenet-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0963586101.USD","HCSG","LU2324357040.USD","BK4585","BK4588","LU0130103400.USD","LU1201861165.SGD","THC","XBI","LU0648000940.SGD","XLV","LU0029874061.USD","BK4581","LU0128526141.USD","BK4185","LABU","BK4137"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":4,"totalSize":422,"code":"91000000","status":"200"}]}}